소아청소년기 이차성 골다공증 환자에서의 파미드로네이트 치료 (Pamidronate Therapy in Children and Adolescents with Secondary Osteoporosis)

서지정보

· 발행기관 : 대한소아내분비학회
· 수록지 정보 : Annals of Pediatric Endocrinology & Metabolism / 16권 / 3호 / 178 ~ 184페이지
· 저자명 : 이지은, 윤주영, 이영아, 임중섭, 신충호, 양세원

초록

Purpose:The aim of this study was to evaluate the efficacy of pamidronate therapy in children and adolescents with secondary osteoporosis.
Methods:Nine patients (7 males, 2 females, 13.2±2.5 years, 10.1-17.4 years) with secondary osteoporosis who had a history of severe bone pain and/or fracture were enrolled. Intravenous pamidronate 1.5 mg/kg (0.5 mg/kg for 3 consecutive days) was given every 6 to 8 weeks for 0.86±0.15 years (6 or 8 cycles). Bone mineral density (BMD) in lumbar spine and femoral neck and their Z-scores were measured before treatment, after the fourth and last cycle (sixth or eighth cycle).
Results:Underlying diseases were as follows; neurofibromatosis type 1 (n=2), epilepsy with/without cerebral palsy (N=2), autoimmune disease treated with steroid (n=2), hematologic malignancy (n=3). Bone pain was relieved in most of the patients after the first cycle of treatment, and no more fracture occurred thereafter. There was a significant increase in BMD Z-score of the lumbar spine and femoral neck after the last cycle of therapy, compared to baseline values (from -3.91±1.79 to 1.86±1.18, in L1-4 and -3.71±1.83 to -2.53±1.77 for femoral neck; P =0.008 and 0.011, respectively). However, there was no significant change in BMD Z-scores between the fourth cycle and the last cycle. Fever developed in 7 out of 9 patients (77.8%), which was relieved by antipyretics. Total serum levels of calcium and phosphorus were significantly decreased (calcium, P =0.008; phosphorus, P =0.015) after pamidronate therapy, and three of them experienced symptomatic hypocalcemia during the first cycle. The growth velocity was normal during follow-up periods (mean, 4.47±1.69 years; range, 1.05 to 6.77 years).
Conclusion:In conclusion, pamidronate can be administered to the patients with secondary osteoporosis, relieving the symptoms and signs effectively and safely. However, its side effects should be monitored during treatment.

영어초록

Purpose:The aim of this study was to evaluate the efficacy of pamidronate therapy in children and adolescents with secondary osteoporosis.
Methods:Nine patients (7 males, 2 females, 13.2±2.5 years, 10.1-17.4 years) with secondary osteoporosis who had a history of severe bone pain and/or fracture were enrolled. Intravenous pamidronate 1.5 mg/kg (0.5 mg/kg for 3 consecutive days) was given every 6 to 8 weeks for 0.86±0.15 years (6 or 8 cycles). Bone mineral density (BMD) in lumbar spine and femoral neck and their Z-scores were measured before treatment, after the fourth and last cycle (sixth or eighth cycle).
Results:Underlying diseases were as follows; neurofibromatosis type 1 (n=2), epilepsy with/without cerebral palsy (N=2), autoimmune disease treated with steroid (n=2), hematologic malignancy (n=3). Bone pain was relieved in most of the patients after the first cycle of treatment, and no more fracture occurred thereafter. There was a significant increase in BMD Z-score of the lumbar spine and femoral neck after the last cycle of therapy, compared to baseline values (from -3.91±1.79 to 1.86±1.18, in L1-4 and -3.71±1.83 to -2.53±1.77 for femoral neck; P =0.008 and 0.011, respectively). However, there was no significant change in BMD Z-scores between the fourth cycle and the last cycle. Fever developed in 7 out of 9 patients (77.8%), which was relieved by antipyretics. Total serum levels of calcium and phosphorus were significantly decreased (calcium, P =0.008; phosphorus, P =0.015) after pamidronate therapy, and three of them experienced symptomatic hypocalcemia during the first cycle. The growth velocity was normal during follow-up periods (mean, 4.47±1.69 years; range, 1.05 to 6.77 years).
Conclusion:In conclusion, pamidronate can be administered to the patients with secondary osteoporosis, relieving the symptoms and signs effectively and safely. However, its side effects should be monitored during treatment.

참고자료

· 없음